AN 2003:591177 CAPLUS
DN 139:149652
TI Preparation of 2-acylaminothiazole derivatives or salts thereof as c-Mpl receptor ligands
IN Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Obitsu, Kazuyoshi; Wakayama, Ryutaro; Hirayama, Fukushi; Suzuki, Ken-ichi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062233	A1	20030731	WO 2003-JP270	20030115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472711	A1	20030731	CA 2003-2472711	20030115
	EP 1466912	A1	20041013	EP 2003-700571	20030115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 4120586	B2	20080716	JP 2003-562111	20030115
	IN 2004KN00942	A	20060217	IN 2004-KN942	20040705
	US 20050153977	A1	20050714	US 2004-500964	20040708
	JP 2008111001	A	20080515	JP 2008-23950	20080204
PRAI	JP 2002-10413	A	20020118		
	JP 2002-10447	A	20020118		
	JP 2003-562111	A3	20030115		
	WO 2003-JP270	W	20030115		
OS	MARPAT 139:149652				

GI



I



AB 2-Acylaminothiazole derivs. or pharmaceutically acceptable salts thereof [I; Ar1 = each (un)substituted aryl, monocyclic aromatic heterocyclyl, or bicyclic condensed heterocyclyl; R1 = each (un)substituted aryl or monocyclic aromatic heterocyclyl; R2 = Q, Q1, R24R25N; wherein n, m = an integer of 1-3; when n or m is an integer of ≥2, CR20R21 and CR22R23 may represent a different group; X = O, S, NR26, C(R27)R28; E, G, J, L = N, CR29; R20-R23, R26-R29 = H, OH, lower alkoxy, each (un)substituted lower alkyl, cycloalkyl, aryl, arylalkyl, aromatic heterocyclyl, aromatic heterocyclylalkyl, nonarom. heterocyclyl, lower alkenyl, lower alkylidene, NH2, or CONH2, CO2H, lower alkoxycarbonyl,

lower alkenyloxycarbonyl, aryl-lower alkoxycarbonyl, aromatic heterocyclyl-lower alkoxycarbonyl, lower alkylcarbonylamino, oxo; R24, R25 = H, each (un)substituted lower alkyl, cycloalkyl, or nonarom. heterocyclyl] are prepared These compds. have an excellent effect of proliferating human c-Mpl-Ba/F3 cells and an activity of increasing platelets (thrombocytosis) based on the effect of promoting the formation of megakaryocytic colonies and are useful in treating thrombopenia. Thus, 2.1 mL Et isonipecotinate was added to a solution of 750 mg 5,6-dichloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]nicotinamide in 10 mL THF, heated to 50°, and stirred for 5 h to give, after workup and silica gel chromatog., 881 mg 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl]-2-pyridyl]piperidine-4-carboxylic acid Et ester which (30 mg) was dissolved in 1 mL MeOH, treated with 0.12 mL 1 M aqueous NaOH solution at room temperature, stirred for 24 h, distilled under reduced pressure, dissolved in EtOAc, treated with 0.2 mL 1 M aqueous HCl solution, stirred, and distilled under reduced pressure, followed by washing the residue with Et2O to give 20 mg 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl]-2-pyridyl]piperidine-4-carboxylic acid hydrochloride (II). II and recombinant human thrombopoietin (rhTPO) at 2.4 ad 0.012 nM, resp., showed 30% of the maximum cell proliferating effect of each compound tested on human c-Mpl-Ba/F3 cell.

IT 570406-91-6P, N-[4-(4-Chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide
570406-92-7P, 3-Chloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(2-hydroxyethoxy)benzamide
570407-00-0P, N-[4-(4-Chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-4-(4-cyanopiperidino)-3,5-difluorobenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-acylaminothiazole derivs. or salts thereof as c-Mpl receptor ligands for proliferating human c-Mpl-Ba/F3 cells and increasing platelets via promoting the formation of megakaryocytic colony)

RN 570406-91-6 CAPLUS
CN Benzamide, N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-3-fluoro-4-hydroxy- (CA INDEX NAME)



RN 570406-92-7 CAPLUS

CN Benzamide, 3-chloro-N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-4-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 570407-00-0 CAPLUS
CN Benzamide, N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-4-(4-cyano-1-piperidinyl)-3,5-difluoro- (CA INDEX NAME)



AN 2007:538881 CAPLUS
DN 146:528295
TI Compositions and methods for treating thrombocytopenia
IN Suzuki, Ken-Ichi; Sugasawa, Keizo
PA Astellas Pharma Inc., Japan
SO PCT Int. Appl., 47pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007054783	A2	20070518	WO 2006-IB3142	20061107
	WO 2007054783	A3	20080703		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006313491	A1	20070518	AU 2006-313491	20061107
	CA 2628848	A1	20070518	CA 2006-2628848	20061107
	US 20070203153	A1	20070830	US 2006-593758	20061107
	EP 1971368	A2	20080924	EP 2006-820862	20061107
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	KR 2008074166	A	20080812	KR 2008-713769	20080609
PRAI	US 2005-734426P	P	20051108		
	WO 2006-IB3142	W	20061107		

OS MARPAT 146:528295
AB The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that agonizes the human TPO receptor by binding to a binding site of the human TPO receptor distinct from the rhTPO binding site.
IT 570406-91-6 570406-92-7 570407-00-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treating thrombocytopenia)
RN 570406-91-6 CAPLUS
CN Benzamide, N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-3-fluoro-4-hydroxy- (CA INDEX NAME)



RN 570406-92-7 CAPLUS
CN Benzamide, 3-chloro-N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-4-(2-hydroxyethoxy)- (CA INDEX NAME)



RN 570407-00-0 CAPLUS
CN Benzamide, N-[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]-4-(4-cyano-1-piperidinyl)-3,5-difluoro- (CA INDEX NAME)



AN 2008:735884 CAPLUS
DN 149:45179
TI TPO receptor agonist combination with other antiviral therapy for the treatment of viral diseases
IN Erickson-Miller, Connie L.; Jenkins, Julian; Theodore, Dickens
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 50pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008073864	A1	20080619	WO 2007-US86918	20071210
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2006-869583P	P	20061212		

OS MARPAT 149:45179
AB The invention discloses a method for treating viral diseases, particularly hepatitis C, in a human, in need thereof which comprises the administration of a combination of therapeutically active agents selected from a TPO receptor agonist and an antiviral therapy selected from an α-interferon, ribavirin, a ribavirin analog, and an HCV antiviral to such human.
IT 570406-98-3 570406-98-3D, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPO receptor agonist combination with other antiviral therapy for treatment of viral diseases)
RN 570406-98-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 570406-98-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT